Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Inclusion Criteria

• •Be premenopausal, between 18 and 40 years of age inclusive on the day of consent
• •Have a clinical history of hypogonadotropic hypogonadism (World health organization \[WHO\] Group I type of anovulation) on the basis of congenital or acquired hypothalamic or pituitary endocrine dysfunction in the presence of qualifying screening laboratories
• •Have no prior treatment cycles with gonadotropins or gonadotropin releasing hormone (GnRH) (gonadotropin naïve)
• •Have discontinued estrogen-progesterone replacement therapy at least one month before the screening procedure
• •Have primary or secondary amenorrhea
• •Have a negative progestin challenge test performed during Screening
• •Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 weeks before initiation of treatment:
• •* Follicle-Stimulating Hormone (FSH): less than (\<)5 international unit per liter (IU/L)
• •* Leutinizing hormone (LH): \<1.2 IU/L (a second Baseline serum LH level will be repeated two weeks after the initial LH draw)
• •* Prolactin: \< 43.3 nanogram per milliliter (ng/mL) (\<1040 milli-international unit per liter \[mIU/L\])
• •* Thyroid Stimulating Hormone (TSH): \<6.5 micro-international units per milliliter (mcIU/mL)
• •* Free Thyroxin (T4): 0.8-1.8 nanogram per deciliter (ng/dL) (11-24 picomole per liter \[pmol/L\])
• •* Testosterone: \<1.0 ng/mL (\<3.5 nanomole per liter \[nmol/L\])
• •Have an endovaginal pelvic ultrasound scan showing (i) no clinically significant uterine abnormality, (ii) no ovarian tumor or cyst, and (iii) less than or equal to (=\<)13 small follicles (mean diameter =\<10 milliliter \[mm\]) on the largest section through each ovary
• •Have a normal cervical pap smear within 6 months of the initial visit
• •Where indicated, have a normal or unchanged computed tomography (CT) scan or nuclear magnetic resonance (NMR) scan of the hypothalamic pituitary region on file
• •Have a body mass index (BMI) between 18.4 and 31.4 kilogram per square meter (kg/m\^2)
• •Be willing and able to comply with the protocol for the duration of the study
• •Have given written informed consent prior to any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to her future medical care